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Objective: Urothelial carcinoma is one of the most common pathological types of bladder cancer. Several
studies have shown that dysregulated microRNAs (miRNAs) play an important role in bladder cancer
progression. We performed the present miRNA microarray analysis in samples of urothelial carcinoma of
the bladder and adjacent normal bladder tissue from Taiwanese patients to investigate dysregulated
miRNAs.
Materials and methods: To detect dysregulated miRNAs in urothelial carcinoma of the bladder, samples of
tumor and adjacent normal tissues were collected from 10 patients. Tissue samples from three patients
were subjected to miRNA microarray analysis, and the remaining tissue samples from the other seven
patients were used to validate the results obtained from the microarray data. Potential targets of these
dysregulated miRNAs were identiﬁed using online databases, including MicroCosm and TargetScan.
Results: A panel of 30 differentially expressed miRNAs with at least fourfold differences in expression
compared with normal controls, including 19 upregulated and 11 downregulated miRNAs, was gener-
ated. The expression levels of miR-30a-5p, miR-30a-3p, miR-99a, miR-130b, miR-133b, miR-135b, miR-
145, miR-195, miR-204, and miR-214 were experimentally veriﬁed using real-time RT-PCR analysis.
Using an online miRNA target database, we discovered that these dysregulated miRNAs potentially
control components of the insulin-like growth factor 1 receptor (IGF1R) signaling pathway.
Conclusion: Our results indicate that dysregulated miRNAs may be involved in bladder cancer patho-
genesis and are potential biomarkers.
Copyright  2014, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
In 2008, there were approximately 386,300 newly diagnosed
bladder cancer cases and 150,200 bladder cancer-related deaths.1
Urothelial carcinoma of the bladder is the most common type of
bladder cancer, and it has complex genetic and phenotypic char-
acteristics. Many risk factors, such as chromosomal anomalies, ge-
netic polymorphisms, epigenetic and genetic mutations, andrtment of Surgery, Shin Kong
in), M001009@ms.skh.org.tw
ciation. Published by Elsevier Taiwenvironmental pollutants, contribute to tumorigenesis and pro-
gression of urothelial carcinoma of the bladder.2,3
MicroRNAs (miRNAs) are noncoding small RNAs that regulate
gene expression in eukaryotes; miRNAs bind to complementary
sequences on target messenger RNA transcripts (mRNAs) and cause
translational repression or target degradation, thus silencing gene
functions.4,5 The human genome encodes over 1000 miRNAs,
which may target approximately 60% of mammalian genes and are
abundant in many human cell types.6e8 Many studies have shown
that miRNAs play a role in the etiology and pathogenesis of cancer
by targeting oncogenes or tumor suppressor genes. Some miRNAs
are dysregulated in many cancer subtypes.9 A distinct miRNA
expression proﬁle has been identiﬁed in high- and low-grade
bladder cancer, deﬁning an invasive bladder tumor phenotype;an LLC. Open access under CC BY-NC-ND license.
Table 2
Primers used for real-time quantitative PCR.
Primer name Primer sequence (50/30)
U6 forward CGCTTCGGCAGCACATATACTA
U6 reverse CGCTTCACGAATTTGCGTGTCA
hsa-miR-30a TGTAAACATCCTCGACTGGAAG
hsa-miR-99a AACCCGTAGATCCGATCTTGTG
hsa-miR-125b TCCCTGAGACCCTAACTTGTGA
hsa-miR-130b ACTCTTTCCCTGTTGCACTAC
hsa-miR-133b TTTGGTCCCCTTCAACCAGCTA
hsa-miR-145 GTCCAGTTTTCCCAGGAATCCCT
hsa-miR-195 TAGCAGCACAGAAATATTGGC
hsa-miR-199a-5p CCCAGTGTTCAGACTACCTGTTC
hsa-miR-204 TTCCCTTTGTCATCCTATGCCT
hsa-miR-214 ACAGCAGGCACAGACAGGCAGT
T.-F. Tsai et al. / Urological Science 25 (2014) 58e64 59the miRNA expression proﬁle may therefore be used as a diagnostic
biomarker.10 Several reports have been published regarding the use
of miRNA microarrays to discover dysregulated miRNAs in uro-
thelial cancer of the bladder using patient tissue, bladder cancer
cell lines, or body ﬂuids; however, none of these studies have been
performed in Taiwanese patients. Because both genetic and envi-
ronmental factors contribute to the risk of bladder cancer, it is
possible that the progression of bladder cancer in Taiwanese pa-
tients is different from western patients.
The present study was performed in an attempt to better un-
derstand the pathogenesis of urothelial carcinoma of the bladder in
Taiwanese patients. Differential miRNA expression in tissue ob-
tained from bladder tumors and adjacent normal bladder tissue
was investigated using miRNA microarrays and real-time quanti-
tative PCR technology to identify dysregulated miRNAs and the
genes that are targeted by these miRNAs.
2. Materials and methods
2.1. Specimen collection
Written informed consent was obtained from all patients, and
the study was approved by the Institutional Review Board of Shin-
Kong Wu Ho-Su Memorial Hospital (IRB#20110814R). Baseline
characteristics of the patients are summarized in Table 1. Ten pa-
tients (5 males and 5 females) with an average age of 60 years
(range 40e77 years) were included in the study. Of these patients,
two male patients and one female patient with Grade 3 tumors
were randomly selected for miRNA microarray analysis, and the
other patients were used for additional evaluations. Urothelial
carcinoma of the bladder was diagnosed histopathologically. Sur-
gical specimens of bladder tumors and adjacent normal bladder
tissues were snap-frozen in liquid nitrogen immediately after
resection.
2.2. RNA preparation
Total RNA was extracted using Trizol Reagent (Invitrogen, Carls-
bad, CA, USA), according to the instructionmanual. PuriﬁedRNAwas
quantiﬁed at O.D. 260 nm using an ND-1000 spectrophotometer
(NanodropTechnology, USA) and the quality of the puriﬁedRNAwas
assessedusing aBioanalyzer 2100 (Agilent Technology,USA)with an
RNA 6000 nano labchip kit (Agilent Technologies, USA). Only cases
with RNA integrity number (RIN) >7 were included.
2.3. RNA labeling and hybridization
A 100-ng sample of total RNA was dephosphorylated and
labeled with pCp-Cy3 using an Agilent miRNA Complete LabelingTable 1
Patient characteristics.
Patients N ¼ 10
Age, y
Mean 60
Range 40e77
Sex
Male 5
Female 5
Histological type
Urothelial carcinoma 10
Squamous cell carcinoma 0
Small cell carcinoma 0
Grade
3 10and Hyb Kit (Agilent Technologies, USA). Then, 2 hybridization
buffer (Agilent Technologies, Palo Alto, CA, USA) was added to the
labeled mixture to reach a ﬁnal volume of 45 mL. The mixture was
heated for 5 minutes at 100C and immediately cooled to 0C. Each
45-mL sample was hybridized onto an Agilent R12 miRNA Micro-
array (Agilent Technologies) at 55C for 20 hours. After hybridiza-
tion, slides were washed for 5 minutes in Gene Expression Wash
Buffer 1 at room temperature and were then washed for 5 minutes
in Gene Expression Wash Buffer 2 at 37C. Slides were scanned on
an Agilent microarray scanner (Agilent Technologies, model
G2505C) at 100% and 5% sensitivity settings. Feature Extraction
(Agilent Technologies) software (version 10.5.1.1) was used for
image analysis.
2.4. Bioinformatics analysis
The target genes for each differentially expressed miRNA were
mainly predicted by MicroCosm (http://www.ebi.ac.uk/enright-
srv/microcosm/htdocs/targets/v5/#).11 Because target gene pre-
diction software can often produce a high rate of false positive re-
sults, we used another program, TargetScan (http://www.
targetscan.org/), to assist in the target gene prediction.12
2.5. Real-time quantitative PCR to validate miRNA expression
To validate the microarray data, we chose 10 differentially
expressed miRNAs, including one upregulated miRNA (miR-130b)
and nine downregulated miRNAs (miR-30a, miR-99a, miR-125b,
miR-133b, miR-145, miR-195, miR-199-5p, miR-204, and miR-214),
for quantitative reverse transcription PCR, using tissues that were
not included in the microarray studies. Synthesis of single-strand
cDNA from the total RNA was performed using the NCode miRNA
First-Strand cDNA Synthesis kit (Invitrogen). Quantitative PCR was
performed on the StepOne plus Real-Time PCR Systems (Invitrogen)
using a qPCR master mix from KAPA biosystems (Woburn, MA,
USA) with speciﬁc primers for each miRNA (Table 2). The cycling
conditions consisted of one cycle at 95C for 2 minutes, followed by
40 cycles at 95C for 15 seconds, 60C for 1 minute, and 72C for 10
seconds, with ﬂuorescence acquisition at 60C in single mode. The
speciﬁc PCR products were conﬁrmed by the results of melting
curve analysis. All PCRs were performed in triplicate, and miRNA
expression levels were quantiﬁed relative to the expression of U6
RNA by employing the DCt value.
2.6. Statistical analysis
The data are presented as the mean SD. Statistical signiﬁcance
between groups was assessed using the Student t test. A value of
p < 0.05 was considered statistically signiﬁcant.
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3.1. miRNAs were differentially expressed in bladder urothelial
carcinoma tissue and adjacent normal bladder tissue
We compared the miRNA expression proﬁle of bladder urothelial
carcinoma tissue and adjacent normal bladder tissue using anmiRNA
microarray and identiﬁed a panel of 49 differentially expressed
miRNAs with at least twofold differences in expression compared
with the normal controls. To further focus on the most dysregulated
miRNAs, we created a list of 30 miRNAs with at least fourfold differ-
ences in expression, as summarized in Table 3. We performed
microarray analysis on three biological replicates. Raw signals greater
than 100 threshold values were considered. Among the high signal
group, 11 miRNAs were upregulated, and 19 were downregulated.
3.2. Validation of differentially expressed miRNAs by real-time
quantitative PCR
We used real-time RT-PCR analysis for miRNA expression to vali-
date the resultsof themicroarrayanalysis. Theexpression levelsof the
10 selected miRNAs (miR-130b, miR-99a, miR-133b, miR-214, miR-
204, miR-145, miR-195, miR-30a, miR-125b, and miR-199a-5p) were
experimentally veriﬁed on bladder urothelial carcinoma tissues andTable 3
miRNAs differentially expressed in bladder urothelial carcinoma tissue and adjacent nor
Probe ID P1Na P1Tb P2Nc P
miRNA Raw Norg Raw Nor Raw Nor Raw
miRNAs with a fourfold upregulation in urothelial carcinoma tissue compared to
hsa-miR-1290 8.10 1.00 130.21 16.08 74.95 1.00 681.
hsa-miR-130b 69.81 1.00 992.93 14.22 43.80 1.00 439.
hsa-miR-203 21.89 1.00 831.49 37.98 204.90 1.00 1543.
hsa-miR-18b 24.18 1.00 137.91 5.70 18.61 1.00 112.
hsa-miR-21*(h) 61.28 1.00 257.04 4.19 55.71 1.00 586.
hsa-miR-96 203.57 1.00 2823.79 13.87 201.75 1.00 858.
hsa-miR-200c 629.60 1.00 15383.70 24.43 2467.13 1.00 12604.
hsa-miR-141 973.39 1.00 24651.70 25.33 4122.56 1.00 27162.
hsa-miR-135b 77.18 1.00 785.78 10.18 22.16 1.00 277.
hsa-miR-210 148.68 1.00 3461.76 23.28 128.93 1.00 1726.
hsa-miR-425 141.84 1.00 1768.81 12.47 241.38 1.00 1669.
miRNAs with a fourfold downregulation in urothelial carcinoma tissue compared
hsa-miR-99a 3277.53 1.00 36.11 0.01 3396.14 1.00 3.
hsa-miR-376c 194.30 1.00 25.30 0.13 492.33 1.00 6.
hsa-miR-376a 201.68 1.00 21.86 0.11 472.63 1.00 5.
hsa-miR-133b 111.40 1.00 7.71 0.07 449.67 1.00 6.
hsa-miR-214 553.26 1.00 99.15 0.18 710.06 1.00 13.
hsa-miR-139-5p 188.51 1.00 8.10 0.04 120.82 1.00 4.
hsa-miR-145*(i) 99.52 1.00 14.83 0.15 353.97 1.00 5.
hsa-miR-1 265.14 1.00 13.09 0.05 1070.10 1.00 0.
hsa-miR-204 8809.56 1.00 8.76 0.01 181.70 1.00 2.
hsa-miR-195 4439.06 1.00 644.44 0.15 2166.45 1.00 270.
hsa-miR-145 1360.89 1.00 182.37 0.13 10800.20 1.00 93.
hsa-miR-30a 19421.80 1.00 301.21 0.02 2328.30 1.00 260.
hsa-miR-199a-3p 4425.76 1.00 1008.40 0.23 9260.35 1.00 174.
hsa-miR-143 621.39 1.00 107.74 0.17 3255.46 1.00 39.
hsa-miR-100 2640.09 1.00 297.48 0.11 3005.98 1.00 9.
hsa-miR-125b 7260.58 1.00 452.30 0.06 15505.60 1.00 51.
hsa-miR-497 1604.66 1.00 236.95 0.15 1090.89 1.00 125.
hsa-miR-199a-5p 1146.67 1.00 235.14 0.21 3646.97 1.00 40.
hsa-miR-30a*(j) 2577.00 1.00 25.87 0.01 228.81 1.00 18.
h, i, j hsa-miR-21*, hsa-miR-145*, and hsa-miR-30a* arise from the 30 arm of their prec
nomenclature of these three miRNAs were changed to hsa-miR-21-3p, hsa-miR-145-3p
a P1N: patient 1 normal tissue.
b P1T: patient 1 tumor tissue.
c P2N: patient 2 normal tissue.
d P2T: patient 2 tumor tissue.
e P3N: patient 3 normal tissue.
f P3T: patient 3 tumor tissue.
g Nor: normalized fold changes.adjacent normal bladder tissueswith anmiRNA-speciﬁc primer using
qRT-PCR. The results of this experiment (Fig.1) showed thatmiR-130b
was upregulated in bladder urothelial carcinoma, and the expression
of miR-99a, miR-133b, miR-214, miR-204, miR-145, miR-195, miR-
30a, miR-125b, and miR-199a-5p were downregulated, as demon-
strated in the microarray analysis. Therefore, these analyses
conﬁrmed the microarray data for these 10 miRNAs.
3.3. Dysregulated miRNAs in bladder urothelial carcinoma may
target genes that are involved in IGF1R signaling
The functions of a given miRNA are dependent on its targeted
genes. Several studies have shown that dysregulated miRNAs in
bladder tumors are involved in controlling the progression of
tumorigenesis.13 To gain more insight regarding the function of
these dysregulated miRNAs, we selected ﬁve microRNAs (miR-99a,
miR-145, miR-195, miR-204, and miR-214) for further study
because these miRNAs have been reported to play important roles
in other types of cancer. Using in silico searches, we cross-compared
two target prediction programs, TargetScan and MicroCosm, in an
attempt to identify potential target genes of these miRNAs.8,14 As
shown in Table 4, there were too many potential targets for any
given miRNA. We therefore employed strategies to further reduce
the number of analyzed miRNAs (Fig. 2). Using a custom-designedmal bladder tissue.
2Td P3Ne P3Tf Avg. fold
(tumor/normal)
S.E.M.
Nor Raw Nor Raw Nor
adjacent normal bladder tissue
78 9.10 67.41 1.00 369.25 5.48 10.22 2.70
14 10.03 16.87 1.00 214.91 12.74 12.33 1.06
79 7.53 26.39 1.00 368.99 13.98 19.83 8.02
50 6.04 0.37 1.00 84.78 226.14 79.30 63.59
82 10.53 14.49 1.00 123.89 8.55 7.76 1.62
96 4.26 19.01 1.00 1561.11 82.14 33.42 21.23
80 5.11 268.02 1.00 5174.35 19.31 16.28 5.01
60 6.59 331.30 1.00 11031.40 33.30 21.74 6.86
10 12.50 3.40 1.00 459.77 135.11 52.60 35.73
16 13.39 48.21 1.00 646.87 13.42 16.70 2.85
05 6.91 48.86 1.00 686.71 14.05 11.15 1.87
to adjacent normal bladder tissue
81 0.01 503.88 1.00 3.01 0.01 0.01 2.94e-4
02 0.01 162.69 1.00 30.56 0.19 0.11 0.04
19 0.01 180.50 1.00 29.19 0.16 0.09 0.04
42 0.01 641.61 1.00 13.02 0.02 0.03 0.02
26 0.02 351.96 1.00 14.95 0.04 0.08 0.04
12 0.03 84.70 1.00 3.58 0.04 0.04 2.47e3
48 0.02 269.74 1.00 13.74 0.05 0.07 0.03
26 0.01 1068.00 1.00 14.08 0.01 0.02 0.01
30 0.01 26.25 1.00 1.73 0.07 0.03 0.02
33 0.12 1183.82 1.00 186.66 0.16 0.14 0.01
48 0.01 12318.90 1.00 432.39 0.04 0.06 0.03
66 0.11 760.42 1.00 109.08 0.14 0.09 0.03
78 0.02 4186.16 1.00 230.30 0.06 0.10 0.06
43 0.01 3427.35 1.00 157.40 0.05 0.08 0.04
62 0.01 857.41 1.00 30.40 0.04 0.05 0.03
15 0.01 4378.75 1.00 80.97 0.02 0.03 0.01
98 0.12 677.43 1.00 80.49 0.12 0.13 0.01
81 0.01 1599.07 1.00 110.05 0.07 0.10 0.05
86 0.08 74.89 1.00 5.77 0.08 0.06 0.02
ursor hairpin hsa-mir-21, hsa-mir-145, and hsa-mir-30a, respectively. The ofﬁcial
and hsa-miR-30a-3p since Release 17 of the miRBase (http://www.mirbase.org/).
Fig. 1. Quantitative RT-PCR validation of the expression of miR-130b, miR-99a, miR-133b, miR-214, miR-204, miR-145, miR-195, miR-30a, miR-125b, and miR-199a-5p in bladder
urothelial carcinoma tissue compared with paired normal tissue. *p < 0.05.
Table 4
Target gene hits of ﬁve selected miRNAs using two different miRNA-target
databases.
miRNA Number of hits by miRNA target prediction program*
MicroCosm TargetScan
hsa-miR-99a 947 41
hsa-miR-145 977 585
hsa-miR-195 962 1071
hsa-miR-204 837 486
hsa-miR-214 1041 430
*Date of data inquiry: December 2011.
T.-F. Tsai et al. / Urological Science 25 (2014) 58e64 61data mining program, we compared potential genes that are tar-
geted by either ﬁve, four, three, or two selectedmiRNAs. Therewere
468, 36, three and zero hits for genes targeted by two, three, four, or
ﬁve selected miRNAs, respectively. We further analyzed the
expression pattern of these target genes using datasets retrieved in
the NCBI’s GEO proﬁles database (http://www.ncbi.nlm.nih.gov/
geo/), which showed that miR-145 and miR-99a target ﬁbroblast
growth factor 3 receptor (FGFR3), a receptor that is overexpressed
in bladder cancer. Furthermore, we also observed that miR-145 andFig. 2. Strategies to identify the target genes of selected downregulated miRNAs. Target gene
The number of genes targeted by ﬁve, four, three, or two miRNAs was determined by an inmiR-214 may target another FGFR family member, FGFR2. In
addition to the multiple-comparison analysis, we collected the
potential targets of all 19 downregulated miRNAs and found that
the downregulatedmiRNAs target several components in the IGF1R
signaling pathway, including several antiapoptotic genes. Table 5
and Fig. 3 note the following ﬁndings: insulin-like growth factor
binding protein 3 (IGFBP3) is a potential target of miR-133b and
miR-145; miR-125bmay target IGF1R; the downstreammediator of
IGF1R signaling, insulin receptor substrate 1 (IRS1), is targeted by
miR-145; phosphatase and tensin homolog (PTEN), a well-known
tumor suppressor gene, is targeted by miR-214; AKT, also known
as protein kinase B (PKB), which plays a key role in multiple cellular
processes, such as glucose metabolism, apoptosis, cell proliferation,
transcription, and cell migration, is targeted by miR-125b and miR-
199a; and cyclin D1 (CCND1), Kristen rat sarcoma viral oncogene
homolog (k-RAS) and beclin-1 (BECN1), which are downstream of
IGF1R signaling, are targeted by miR-195, miR-143, and miR-30a,
respectively. Several dysregulated miRNAs we found are also
involved in the antiapoptotic pathway. For example, Bcl2-
antagonist/killer 1 (BAK1) is a potential target of miR-125b; miR-
133b, and miR-204 may target myeloid leukemia cell differentia-
tion protein (MCL1); and miR-133b may also target anothers of downregulated miRNAs in tumor tissues were identiﬁed by a query in MicroCosm.
-house data mining program.
Fig. 3. Dysregulated miRNAs in urothelial carcinoma target genes that are involved in IG
downstream antiapoptotic pathways are illustrated. The miRNAs that are predicted to targ
Table 5
Dysregulated miRNAs in urothelial carcinoma and their potential target genes
involved in IGF1 signaling and antiapoptotic pathways.
IGF1 signaling pathway Antiapoptotic pathway
Target gene miRNAs Target gene miRNAs
IGF1R miR-125b BAK1 miR-125b
miR-99a
miR-100
IGFBP3 miR-133b MCL1 miR-133b
miR-145 miR-204
IRS1 miR-145 BCL2L2 miR-133b
PTEN miR-214 BCL2L11 miR-195
AKT1 miR-125b BCL2 miR-204
miR-199a-3p
CDK6 miR-30a* DAPK1 miR-214
miR-125b
miR-195
CCND1 miR-195
kRas miR-143
BECN1 miR-30a
Results were from the multiple-comparison analysis with GEO proﬁle, MicroCosm
and TargetScan databases.
T.-F. Tsai et al. / Urological Science 25 (2014) 58e6462antiapoptotic family member, Bcl2-like 2 (Bcl2l2, Bcl-w). Bcl2-
like11 (Bcl2l11), Bcl2, and death-associated protein kinase 1
(DAPK1) are potential targets for miR-195, miR-204, and miR-214,
respectively. These results demonstrate that most of the down-
regulated miRNAs we identiﬁed in urothelial carcinoma of the
bladder potentially target genes involved in IGF1R signaling as well
as several antiapoptotic proteins. When these miRNAs were
downregulated in cancer cells, the expression of their targeted
genes was not controlled, resulting in the magniﬁcation of pro-
survival signals for cancer cells.
4. Discussion
miRNAs regulate one-third of all protein coding genes and play a
critical role in the pathophysiology of various human diseases.
Studies have shown that miRNAs regulate different biological
processes, such as glucose metabolism,15 insulin regulation,16 lipid
metabolism,17,18 cell differentiation, and the inﬂammatory
response.19 Therefore, listing miRNAs that are differentially
expressed between tumor and normal tissues provides an oppor-
tunity to identify the miRNAs that are most likely to be involved inF1R signaling and antiapoptotic pathways. Selected genes in IGF1R signaling and its
et these genes are listed.
T.-F. Tsai et al. / Urological Science 25 (2014) 58e64 63cancer, to identify new diagnostic/prognostic biomarkers, and to
develop novel therapeutic agents. The majority of the published
papers reporting miRNA expression proﬁling analysis using
microarray technology are from western countries. We reported
here that the expression proﬁle of miRNAs differed signiﬁcantly
between bladder urothelial carcinoma tissue and adjacent normal
bladder tissue in Taiwanese bladder cancer patients. The micro-
array data were validated by real-time RT-PCR analysis for 10
miRNAs (Fig. 1). These miRNAs may be involved in urothelial car-
cinoma of the bladder and are potential biomarkers.
In this study, we identiﬁed 11 upregulated and 19 down-
regulated miRNAs in bladder cancer. Among the upregulated
miRNAs, miR-18b, miR-21*, miR-96, and miR-130b have been re-
ported to be upregulated in microarray studies.10,20 Recently, a
study from China using a deep sequencing technique to proﬁle
miRNA expression signatures revealed that miR-96, miR-141, and
miR-200c are upregulated in bladder cancer. 21 Among the down-
regulated miRNAs, miR-1, miR-30a*, miR-99a, miR-100, miR-125b,
miR-133b, miR-143, miR-145, miR-145*, miR-204, miR-214, and
miR-376a were reported to be downregulated using a microarray
technique.10,20 miR-1, miR-99a, miR-100, miR-125b, miR-143, miR-
145, miR-145*, and miR-195 have been demonstrated to be
downregulated in a Chinese study of bladder cancer.21 Our data are
consistent with other reports on miRNA expression in bladder
cancer. However, our work identiﬁed several unique dysregulated
miRNAs that need further investigation.
miR-130b has been reported to be upregulated in bladder can-
cer.10 However, its function in the progression of bladder cancer is
still unknown. The role of miR-130b in tumor formation is
controversial. For example, multidrug resistance in ovarian cancer
was induced by epigenetic silencing of miR-130b, which targets
colony-stimulating factor 1 (CSF-1).22 The expression level of miR-
130b was signiﬁcantly downregulated in pancreatic cancer, and
overexpression of miR-130b suppressed the proliferation of
pancreatic cancer cells in vitro and in vivo.23 These indicated that
miR-130b functions as a tumor suppressor and is downregulated in
ovarian and pancreatic cancer cells. However, in hepatocellular
carcinoma (HCC) and endometrial cancer, miR-130b was upregu-
lated and targeted protein 53-induced nuclear protein 1
(TP53INP1) and DICER1, promoting tumor progression. Further
research is needed regarding the functional roles of miR-130b in
bladder cancer.
miR-1 and miR-133a cluster on the same chromosomal loci and
have been described asmuscle-speciﬁc miRNAs. These twomiRNAs
are involved in the regulation of muscle cell growth and differen-
tiation. Altered expression of miR-1 and miR-133 in the heart also
contributes to cardiovascular diseases, such as cardiac ischemia,
cardiac hypertrophy, and arrhythmias.24 Expression levels of miR-1
and miR-133a have also been reported to be dysregulated in colon
cancer.25 Studies have shown that miR-145, miR-133a, and miR-
133b are possible tumor suppressors with conserved sequences
in the 30-UTR of fascin homolog 1 (FSCN1). These miRNAs inhibit
FSCN1 expression and target FSCN1 in esophageal squamous cell
carcinoma.26 In bladder cancer, miR-145 and miR-133a have been
reported to be downregulated and to directly control oncogenic
FSCN1.27 Our results showed that miR-1, miR-133a, miR-133b, miR-
143, and miR-145 were downregulated in urothelial carcinoma of
the bladder. Therefore, these miRNAs may contribute to tumori-
genesis and may serve as tumor biomarkers. Furthermore, FGFR3 is
considered to be an important marker for bladder cancer.28 FGFR3
is commonly mutated and dysregulated in bladder cancer.29 miR-
99a and miR-100 have been reported to regulate the expression
of FGFR3 in bladder cancer in a previous study from the United
Kingdom that used microarrays to proﬁle miRNA expression.10 We
also detected the downregulation of miR-99a and miR-100 inTaiwanese patients, suggesting that the regulation of FGFR3 by
these miRNAs may play an important role in the tumorigenesis of
bladder cancer in Taiwanese patients, as has been reported in
western countries. IGF1R is a protein found on the surface of human
cells that is activated by IGF1 and by a related hormone, IGF2. It
belongs to a large class of tyrosine kinase receptors. IGF1Rmediates
the effects of IGF-1, which is a polypeptide protein hormone
structurally similar to insulin. IGF-1 plays an important role in
growth and continues to have anabolic effects in adults. IGF1R is
implicated in several cancers, including breast, prostate, and lung
cancers, and is considered to be a therapeutic target in cancer
treatment.30 Our data showed that several dysregulated miRNAs
are involved in the regulation of components belonging to the
IGF1R signaling pathway and antiapoptotic genes downstream of
IGF1R signaling. For instance, miR-99a was previously demon-
strated to target FGFR3 in bladder cancer and targets IGF1R in HCC,
and head and neck squamous cell carcinoma.31,32 miR-145 targets
IRS1 in colon cancer cells.33 In prostate cancer, the loss of miR-125b
potentiates a translational response to activation of the AKT
pathway.34 An inverse correlation between miR-214 and PTEN was
observed in epithelial ovarian and breast cancer cells.35,36 miR-195
targeting of CCND1 has been proven in HCC, colorectal cancer, and
breast cancer. 37e39
However, antiapoptotic genes downstream of IGF1Rmay also be
controlled by downregulated miRNAs in bladder cancer. miR-204
has been reported to target MCL1 in leukemia.40 Elevation of
miR-204 expression enhances treatment responsiveness of gastric
cancer by targeting Bcl2.41 In lung cancer, miR-133b targets MCL1
and Bcl2l2 to induce cancer cell death.42 These ﬁndings further
imply that IGF1R and its downstream antiapoptotic pathway
(rather than FGFR3 signaling) may also play an important role in
the pathogenesis of bladder cancer in Taiwanese patients. However,
further investigation is needed to conﬁrm the direct interaction of
these dysregulated miRNAs with the potential target genes iden-
tiﬁed in this study. Our group is currently undertaking research on
these dysregulated miRNAs by studying the relationship of their
target genes with bladder cancer tumorigenesis.
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